![Fig. 6. Tumor antigen-specific IFN-γ production by responding splenocytes harvested from vaccinated mice (ELISPOT). / (A) Splenocyte IFN- γ production specific for tumor cells (EG.7-OVA) was shown in group 3 mice by ELISPOT assay. Spleen cells (5 × 106 cells/well) from each group were incubated for 24 hours with EG7-OVA or irrelevant tumor cell (EL4). (On day 21, group 3 vs group 2 [P < .05]; and groups 1, 4 vs group 3 [P < .01]; on day 28, group 3 vs group 1 [P < .01]; group 3 vs group 2 [P < .01]; group 3 vs group 4 [P < .005]). (B) These specific cells were also OVA peptide-specific CD8+ T cells. Spleen cells (5 × 106 cells/well) from each group were incubated for 36 hours with OVA peptide (SIINFEKL) or irrelevant peptide (SIINFKEL). These peptide-specific spots in each group were similar to the responding spots for EG7-OVA in Figure 6A. (On day 21, group 3 vs groups 2, 4 [P > .05]; group 1 vs group 3 [P < .01]; on day 28, group 3 vs group 1 [P < .0001]; group 3 vs group 2 [P < .0001]; group 3 vs group 4 [P < .0001]). Mean values are shown for 3 mice at each time point.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/98/7/10.1182_blood.v98.7.2143/5/h81911575006.jpeg?Expires=1722387638&Signature=m4LzjtzECaxbyDnK4Z3FhKuHLQolMx0SlJicA6jSQFxGdaenA8suZ-tg57FxKvdVPDLM0U0wRP2JG-cveavH3LRN3MXD878Z7h0D0qHY1FeLh~kvJGGLkjpU3CX8K23Xty2PLqDOlMqFfZ~Qw3O~f1QoW0-78VcUXyLrkHsjmiKcgcgSxA3uju6wl3SmcYzGNryz~iwvEx8mxGRwE9O45Q98FHOIZqELDoTVi0WZCM~vcQqGzp6LT8n9XQ5tWz0LSIYqr8Np9P1n1t04pAMQxJDzsZH6FW3-xB46ZCkxV2d28QFZ8xw-R~mWAGqipXJQAaX4Eu2vVXLGCgXznNIkNQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Tumor antigen-specific IFN-γ production by responding splenocytes harvested from vaccinated mice (ELISPOT).
(A) Splenocyte IFN- γ production specific for tumor cells (EG.7-OVA) was shown in group 3 mice by ELISPOT assay. Spleen cells (5 × 106 cells/well) from each group were incubated for 24 hours with EG7-OVA or irrelevant tumor cell (EL4). (On day 21, group 3 vs group 2 [P < .05]; and groups 1, 4 vs group 3 [P < .01]; on day 28, group 3 vs group 1 [P < .01]; group 3 vs group 2 [P < .01]; group 3 vs group 4 [P < .005]). (B) These specific cells were also OVA peptide-specific CD8+ T cells. Spleen cells (5 × 106 cells/well) from each group were incubated for 36 hours with OVA peptide (SIINFEKL) or irrelevant peptide (SIINFKEL). These peptide-specific spots in each group were similar to the responding spots for EG7-OVA in Figure 6A. (On day 21, group 3 vs groups 2, 4 [P > .05]; group 1 vs group 3 [P < .01]; on day 28, group 3 vs group 1 [P < .0001]; group 3 vs group 2 [P < .0001]; group 3 vs group 4 [P < .0001]). Mean values are shown for 3 mice at each time point.
